Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
The FDA granted accelerated approval for INOVIO's VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (RRP). This represents the first U.S. FDA-approved DNA medicine and validates INOVIO's platform technology, with a commercial launch expected in Q1 2027.
“With the approval of VOCERYQ, we believe our DNA medicine platform has the potential to transform the treatment paradigm for RRP by offering a patient-centric treatment option. VOCERYQ is designed to deliver what we understand matters most to patients, which is the reduction of the surgical burden caused by RRP.”
Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer
Flowco Holdings Inc. announced that its Board of Directors approved a $150 million increase to its existing share repurchase program, bringing the total authorization to $200 million. The program allows for opportunistic repurchases of Class A common stock in the open market or through private transactions and has no expiration date.
Lumentum reported Q1 fiscal 2027 net revenue of $1.26 billion, a 136.5% increase year-over-year, driven by strong demand for pump lasers and optical circuit switches. The company also announced a major NPO/CPO win with purchase commitments exceeding $5 billion and provided strong Q2 guidance reflecting continued sequential growth.
Term
Q1 2027
“Lumentum built on its strong momentum in the first fiscal quarter of 2027, delivering growth across all our businesses, with pump lasers and optical circuit switches (OCS) being the leading contributors. During the quarter, we secured our second major NPO/CPO win, backed by purchase commitments exceeding $5 billion. Additionally, our OCS demand visibility has expanded significantly in recent months, positioning optical switching to become a multi-billion-dollar annual revenue stream. Finally, we continue to see strength in our cloud modules business which is showing improvement on the gross margin line.”
Michael Hurlston, President and CEO
“Looking ahead, we anticipate adding approximately $350 million in sequential growth in our second quarter, a figure greater than the quarterly revenue of the whole company just two years ago. Furthermore, we project our second quarter operating margin to exceed 45 percent.”
Boardwalk Pipeline Partners, LP reported net income of $461.1 million for the nine months ended September 30, 2026, a slight increase from $454.3 million in the prior year period. Total operating revenues grew to $1.81 billion, driven by higher transportation and product sales, while the company significantly increased capital expenditures to $550.2 million.
Seaport Therapeutics is a clinical-stage therapeutics company that recently transitioned to public markets, reporting 53,530,550 shares of voting common stock outstanding as of October 2026. The filing indicates the company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company, focusing on advancing its clinical pipeline and research programs.
Krystal Biotech reported third quarter 2026 financial results, highlighted by $127.3 million in global VYJUVEK net product revenue, a 30% year-over-year increase. The company ended the quarter with a strong cash position of $1.2 billion and announced a new $400 million share repurchase program. Additionally, the company completed pricing negotiations for VYJUVEK in Germany and Italy and reported positive clinical data for its KB113 candidate in Gorlin syndrome.
“Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline. Our financial strength allows us to invest fully in these programs and our global commercial expansion while returning capital to shareholders. The $400 million share repurchase program, under which we expect to repurchase shares opportunistically over the next two years, reflects our confidence in Krystal’s long-term growth prospects and our commitment to disciplined capital allocation.”
Krish S. Krishnan, Chairman and Chief Executive Officer
Krystal Biotech reported a strong third quarter in 2026, with product revenue increasing to $127.3 million compared to $97.8 million in the prior year. Net income for the nine months ended September 30, 2026, rose to $173.8 million, supported by significant growth in cash and investments totaling over $1.19 billion.
Axsome Therapeutics reported Q3 2026 financial results with total net product revenue of $259.7 million, a 52% year-over-year increase driven by strong sales of Auvelity and Sunosi. The company significantly narrowed its net loss to $12.9 million compared to $47.2 million in the prior year period, surpassing a $1 billion annual revenue run rate.
Term
Q3 2026
“Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annual run rate. We expect sustained momentum driven by strong underlying demand for Auvelity in major depressive disorder, and continued acceleration of new patient initiations in Alzheimer’s disease agitation.”
Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics
TripAdvisor Divestiture to American Express Travel Related Services Company, Inc. for $700M
Tripadvisor completed the sale of its European online restaurant reservation platform, TheFork, to American Express for $700 million in cash. The deal includes a 12-month transition services agreement to facilitate the separation of the business. Tripadvisor expects to discuss the impact of this significant disposition during its Q3 2026 earnings call.
Value
$700M
Counterparty
American Express Travel Related Services Company, Inc.
Tempus AI reported total net revenue of $411.5 million for the third quarter of 2026, a 23% increase year-over-year, driven by growth in both Diagnostics and Data and Applications segments. The company significantly narrowed its net loss to $14.9 million compared to $80.0 million in the prior year period, aided by a substantial $108.9 million gain on marketable equity securities.
Seaport Therapeutics reported third quarter 2026 financial results, ending the period with $403.8 million in cash and investments. The company highlighted clinical progress, including the dosing of the first patient in a Phase 2a trial for GlyphAgo and positive Phase 1 driving simulation data for GlyphAllo. Management expects current capital to fund operations into 2029, covering three upcoming mid-to-late-stage clinical data readouts.
“Over the last few months, Seaport met two key clinical milestones – we dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance, and demonstrated that GlyphAllo did not impair next-morning driving performance in a Phase 1 driving trial.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“Seaport is well-capitalized, with cash runway through all three of our upcoming mid-to-late-stage clinical data readouts. There are a billion people living with mental illness – waiting and hoping for better medicines. We are committed to our mission to bring better days to patients and their families.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
Marriott International reported third quarter 2026 results with worldwide RevPAR increasing 6.5% and net income reaching $794 million. The company achieved record development pipeline growth with over 634,000 rooms and returned $1.3 billion to shareholders through stock repurchases during the quarter.
Term
3 years
“Our excellent third quarter results reflected continued momentum across our business, the benefits of our global scale, and the power of our brands and revenue engines. Global RevPAR increased 6.5 percent in the third quarter, on higher ADR and occupancy. In the U.S. & Canada, RevPAR rose over 7 percent, with broad-based growth across customer segments and chain scales.”
Anthony Capuano, President and Chief Executive Officer
“Our global scale, compelling portfolio of brands, industry-leading Marriott Bonvoy loyalty program and dedicated associates, together with our robust development pipeline and disciplined execution, give us confidence in our ability to deliver sustainable, long-term growth.”
Anthony Capuano, President and Chief Executive Officer
Vertical Data Inc. announced it intends to issue shares of common stock in a private placement transaction for gross proceeds of approximately $4.2 million. The company also disclosed a non-binding term sheet for a GPU-as-a-Service arrangement with a cloud provider involving 16,000 NVIDIA GPUs with a potential contract value of $2.8 billion.
Information Services Group (ISG) reported Q3 2026 revenues of $65.1 million, up 4.4% year-over-year, driven by significant growth in Asia Pacific and AI-related revenues. The company achieved its highest quarterly margin in four years at 15.4% and generated $12.3 million in cash from operations, the highest in five years.
Term
Q3 2026
“ISG delivered a robust financial performance in the third quarter, with strong cash generation, expanding margins and solid revenue growth. Revenue in the quarter was driven by a return to growth in Asia Pacific, up 47 percent; AI-related revenues reaching over $30 million for the first time and recurring revenues continuing to build, up 7 percent. This mix of growth helped drive margin expansion to 15.4 percent, our highest quarterly margin in four years. AI is amplifying the value of our portfolio, with research that informs choices, advisory execution that secures outcomes for enterprises and governance that sustains value. We are well-positioned to close out an outstanding 2026 and continue our momentum into the new year.”
Eton Pharmaceuticals Research Collaboration with Baylor College of Medicine
Eton Pharmaceuticals has entered into a license and development agreement with Baylor College of Medicine to evaluate mecasermin (ET-900) for the treatment of infantile and epileptic spasms. The partnership includes an investigator-sponsored Phase 2 clinical study with patient dosing targeted for Q1 2027, following the submission of an Investigational New Drug application to the FDA.
Tempus AI reported record Q3 2026 revenue of $411.5 million, a 23% year-over-year increase driven by strong growth in its Oncology and Data & Applications segments. The company narrowed its net loss to $14.9 million and raised its full-year 2026 revenue guidance to a range of $1.60 billion to $1.605 billion.
Term
Q3 2026
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications. These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive our performance quarter after quarter.”
Alpine Income Property Trust Signs $117M M&A Deal with institutional owner
Alpine Income Property Trust completed the acquisition of a 13-property industrial portfolio for $117.3 million from an institutional seller. The portfolio totals 1.9 million square feet across 11 states and is 100% leased to nine tenants under absolute triple-net leases. The acquisition was funded using borrowings from the company's revolving credit facility.
Accendra Health $150M Debt Financing with PNC Bank, National Association
Accendra Health's subsidiaries entered into an amendment to their Receivables Purchase Agreement with PNC Bank, extending the $150 million facility's termination date to October 2029. The amendment also revises account control provisions and reporting obligations while maintaining the existing facility size to ensure liquidity. The program is backed by the company's accounts receivable portfolio through its Accendra Funding and Byram Healthcare units.
Nebius Group Insider John Wilson Boynton IV Sells $57.6K of Stock
John Wilson Boynton IV sold 333 shares of Nebius Group N.V. at $173.07 a share, worth $57.6K in total on Oct 29, 2026. Shares held after the trade: 403,189 (-0.1%).
Atrium Therapeutics announced nonclinical data for its lead therapy ATR 1072 showing reversal of cardiac glycogen accumulation and improvement in hypertrophy in a mouse model of PRKAG2 syndrome. The company plans to present these findings at the American Heart Association Scientific Sessions 2026 and expects initial Phase 1/2 clinical proof-of-concept data in the second half of 2027.
Kosmos Energy amended and restated its commercial debt facility (A&R RBL), extending the final maturity date to April 1, 2033, and reducing the total facility size to $1.2 billion. The agreement includes an option to increase commitments by up to $550 million and establishes a new $200 million minimum liquidity covenant starting in 2027.
Sinda Ltd. completed its initial public offering in June 2026, significantly increasing its cash position to $305.6 million and total stockholders' equity to $311.5 million. The company remains in the exploration stage, reporting a net loss of $43.1 million for the first nine months of 2026 as it scales exploration and administrative activities in Mexico.
U.S. GoldMining provided an operational update on infrastructure developments in the West Susitna Mineral District that benefit its Whistler Gold-Copper Project. Key updates include the U.S. Army Corps of Engineers initiating an expedited emergency permitting process for the state-led West Susitna Access Road and a $249 million federal grant awarded to complete the Port MacKenzie rail extension.
Kosmos Energy reported its third quarter 2026 financial results, generating a net loss of $43 million and adjusted net income of $35 million. The company highlighted a 6% year-over-year increase in net production to 69,200 boepd and a significant reduction in net debt by over $500 million year-to-date. Additionally, the company completed a $1.2 billion reserve-based lending (RBL) facility amendment and extension to April 2033.
“Kosmos continued to make meaningful progress during the third quarter against the four objectives we established at the beginning of the year: increase production, lower costs, reduce debt and advance our quality growth opportunities. Through a combination of strong operational execution, reduced costs, disciplined capital allocation and proactive financing, we continue to strengthen our business.”
Andrew G. Inglis, Chairman and Chief Executive Officer
“Financially, 2026 continues to represent a year of significant progress for Kosmos. Since the beginning of the year, we have materially improved liquidity, reduced debt, extended maturities, lowered leverage and strengthened the overall credit profile of the company. With the RBL re-financing complete, we have further increased our financial resilience and will now look to address our 2028 bond maturities.”
Andrew G. Inglis, Chairman and Chief Executive Officer
Steakholder Foods CEO Arik Kaufman Buys $38.2K of Stock
Arik Kaufman, CEO, bought 96,826 shares of Steakholder Foods Ltd. at $0.3847 to $0.4 a share (average $0.3942) in 2 transactions, worth $38.2K in total between Oct 29, 2026 and Oct 30, 2026. Shares held after the trade: 112,623 (+114.0%).
News Corp provided a daily update on its existing $1 billion stock repurchase program as required by Australian Securities Exchange (ASX) rules. The filing discloses ongoing buy-back transactions for the company's Nasdaq-listed Class A and Class B common stock. No ASX-listed CDIs are being repurchased under this specific program.
IDEXX Laboratories reported third quarter 2026 revenue of $1.21 billion, up 10% year-over-year, driven by strong growth in its Companion Animal Group. The company delivered EPS of $4.01 and raised its full-year 2026 revenue and EPS guidance based on strong recurring diagnostics performance.
Term
Q3 2026
“IDEXX delivered exceptional third quarter results, reflecting strong commercial execution and momentum from our innovation-driven growth strategy. Innovations like IDEXX inVue Dx with FNA, and IDEXX Cancer Dx becoming a multi-cancer panel, are helping practices detect disease earlier and work more efficiently.”
Mike Erickson, President and Chief Executive Officer
Ferrellgas Partners, L.P. has furnished a formal investor presentation dated November 2026 for use in future meetings with current and potential investors and analysts. The presentation provides an overview of the company's business operations and strategic outlook.
Lazard Signs $742M M&A Deal with Campbell Lutyens Holdings Limited
Lazard completed its acquisition of Campbell Lutyens, launching a new global private capital advisory business called Lazard CL. The total consideration includes approximately $448.8 million in initial equity (9.65 million shares at $46.50), $93.2 million in initial cash, $115 million in deferred consideration, and up to $85 million in contingent earn-outs.
Value
$742M
Counterparty
Campbell Lutyens Holdings Limited
“We are thrilled to launch our third global business, Lazard CL. By pairing leading global positions in primary fundraising and secondary advisory with our world-class M&A, capital markets, and restructuring expertise, we are deepening the connectivity between our advisory businesses and strengthening our reach across both the largest strategic transactions and private capital activity.”
CNA Financial reported net income of $196 million for the third quarter of 2026, a decrease from $403 million in the prior year period, primarily driven by higher insurance claims and policyholders’ benefits. Total revenues remained stable at $3.82 billion, while the company experienced a significant total comprehensive loss of $837 million due to net unrealized losses on investments.